Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

• Main Authors: Gabriel Tremblay, Patrick Daniele, Janis Breeze, Lingling Li, Jatin Shah, Sharon Shacham, Michael Kauffman, Monika Engelhardt, Ajaj Chari, Ajay Nooka, Dan Vogl, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Paul Richardson, Noa Biran, David Siegel, Philip Vlummens, Chantal Doyen, Thierry Facon, Mohamad Mohty, Nathalie Meuleman, Moshe Levy, Luciano Costa, James E. Hoffman, Michel Delforge, David Kaminetzky, Katja Weisel, Marc Raab, David Dingli, Sascha Tuchman, Frenzel Laurent, Ravi Vij, Gary Schiller, Philippe Moreau, Joshua Richter, Martin Schreder, Klaus Podar, Terri Parker, Robert Frank Cornell, Karlin Lionel, Sylvain Choquet, Jagannath Sundar
• Format: Article
• Language: English
• Published: BMC 2021-09-01
• Series: BMC Cancer
• Subjects: Patient reported outcomes; Health-related quality of life; FACT-MM; Multiple myeloma; Selinexor
• Online Access: https://doi.org/10.1186/s12885-021-08453-9

Abstract Background Selinexor is an oral, selective nuclear export inhibitor. STORM was a phase 2b, single-arm, open-label, multicenter trial of selinexor with low dose dexamethasone in patients with penta-exposed relapsed/refractory multiple myeloma (RRMM) that met its primary endpoint, with overall response of 26% (95% confidence interval [CI], 19 to 35%). Health-related quality of life (HRQoL) was a secondary endpoint measured using the Functional Assessment of Cancer Therapy – Multiple Myeloma (FACT-MM). This study examines impact of selinexor treatment on HRQoL of patients treated in STORM and reports two approaches to calculate minimal clinically important differences for the FACT-MM. Methods FACT-MM data were collected at baseline, on day 1 of each 4-week treatment cycle, and at end of treatment (EOT). Changes from baseline were analyzed for the FACT-MM total score, FACT-trial outcome index (TOI), FACT-General (FACT-G), and the MM-specific domain using mixed-effects regression models. Two approaches for evaluating minimal clinically important differences were explored: the first defined as 10% of the instrument range, and the second based on estimated mean baseline differences between Eastern Cooperative Oncology Group performance status (ECOG PS) scores. Post-hoc difference analysis compared change in scores from baseline to EOT for treatment responders and non-responders. Results Eighty patients were included in the analysis; the mean number of prior therapies was 7.9 (standard deviation [SD] 3.1), and mean duration of myeloma was 7.6 years (SD 3.4). Each exploratory minimal clinically important difference threshold yielded consistent results whereby most patients did not experience HRQoL decline during the first six cycles of treatment (range: 53.9 to 75.7% for the first approach; range: 52.6 to 72.9% for the second). Treatment responders experienced less decline in HRQoL from baseline to EOT than non-responders, which was significant for the FACT-G, but not for other scores. Conclusion The majority of patients did not experience decline in HRQoL based on minimal clinically important differences during early cycles of treatment with selinexor and dexamethasone in the STORM trial. An anchor-based approach utilizing patient-level data (ECOG PS score) to define minimal clinically important differences for the FACT-MM gave consistent results with a distribution-based approach. Trial registration This trial was registered on ClinicalTrials.gov under the trial-ID NCT02336815 on January 8, 2015.